This is the property of the Daily Journal Corporation and fully protected by copyright. It is made available only to Daily Journal subscribers for personal or collaborative purposes and may not be distributed, reproduced, modified, stored or transferred without written permission. Please click "Reprint" to order presentation-ready copies to distribute to clients or use in commercial marketing materials or for permission to post on a website. and copyright (showing year of publication) at the bottom.

Michael J. Wise

By Pat Broderick | Apr. 19, 2012

Intellectual Property

Apr. 19, 2012

Michael J. Wise

See more on Michael J. Wise

Perkins Coie LLP Los Angeles



Wise figures part of his varied practice - patent interferences - eventually will be rendered obsolete after the new patent reforms take effect March 2013.


Patent interference proceedings are a by-product of the United States' "first to invent" system, when two individuals filing for the same invention butt heads and it's up the patent office to sort it all out.


"This is very common in the biotech area," Wise said, "because people are looking at the same drugs and biologics."


He added, "Most of the major biologic drugs have had some kind of interference proceeding, with different companies working to be the first."


But the switch in the U.S. to a "first to file" system, common in other countries, should generate plenty of other work, he said.


"My practice will migrate toward post-grant and inter partes reviews," Wise added.


This, he said, will likely be more lucrative for attorneys, because there will be more of these procedures, which "I believe will make up for the loss of revenue from the phase-out of interferences."


Not that it will be any less stressful than fielding interferences.


"Everybody has to be on their toes, monitoring competitors' patents and what is being prosecuted in the patent office in order to timely contest a grant of patents," Wise said.


If the window for having post-grant reviews is missed, Wise added, "it will diminish your ability to attack a patent in the patent office."


Serving as managing partner for the firm's China region, Wise heads up its China IP practice.


Among his significant matters, Wise represents Ruyan Investments (Holdings) Ltd, an innovator in the field of electronic cigarette technology, in two lawsuits pending against a number of U.S. e-cigarette sellers for alleged infringement of a U.S. patent that's based on a Chinese invention. Ruyan v. Smoking Everywhere Inc., CV 11-0367 GAF (FFMx) (C.D. Cal.); Ruyan v. Vapor Corp., CV 11-6268 GAF (FFMx) (C.D. Cal.).

- PAT BRODERICK

<!-- Michael J. Wise -->

#309515

For reprint rights or to order a copy of your photo:

Email jeremy@reprintpros.com for prices.
Direct dial: 949-702-5390

Send a letter to the editor:

Email: letters@dailyjournal.com